MNPR News and Press, Monopar Therapeutics Inc. From 05/07/25

2025-05-07 19:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN18...

WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840...

2025-04-01 16:15:00 ET The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ. After dropping to a l...

2025-03-31 13:05:16 ET More on Monopar Therapeutics Monopar Therapeutics: Strong Data, But There Are Risks Monopar a new overweight at Piper Sandler on rare disease asset Seeking Alpha’s Quant Rating on Monopar Therapeutics Historical earnings data for...

WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summar...

HG Holdings Inc (STLY) is expected to report for quarter end 2024-12-31 Savara Inc. (SVRA) is expected to report $-0.11 for Q4 2024 Reborn Coffee Inc. (REBN) is expected to report for quarter end 2024-12-31 VSee Health Inc. (VSEE) is expected to report for Q4 2024 IceCure Medical ...

2025-03-19 10:27:11 ET More on Monopar Therapeutics Monopar Therapeutics: Strong Data, But There Are Risks Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways Monopar Therapeutics announces pricing of $40M public offering of common stock ...

2025-03-04 04:54:57 ET Summary Monopar Therapeutics' lead asset, ALXN1840, shows superior copper mobilization in Wilson Disease compared to standard care, with positive phase 3 trial results. The market for Wilson Disease treatments is small, with limited pricing power due to exis...

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics PR Newswire Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease NORTH CHICAGO, Ill....